4BIO Capital
Venture capital firm · Founded 2014 · London · London ↗
4BIO Capital is a London-based international venture capital firm focused solely on advanced therapies — cell and gene therapy, RNA-based therapy, targeted therapies and the microbiome — investing in and building early-stage companies developing treatments for areas of high unmet medical need.
Tier reflects published scale and track-record signals. It is not a rating of the firm as a partner.
This profile is unclaimed. Built from public sources. If you're a partner or employee at 4BIO Capital, you can claim it.
Claim this profileHow claiming worksKey numbers
Assets under management
$264M
Latest fund
LAST CHECKED NOV 2026
Funds
3
Check size
LAST CHECKED NOV 2026
Stages
SeedSeries A
Sectors
Advanced Therapies
FIGURES ARE AS PUBLISHED IN THE CATALOG RECORD 1 · PER-FIGURE AS-OF DATES ARE NOT YET IN THE CATALOG
Track record
Hits
- Autolusipo
4BIO portfolio company Autolus completed its Nasdaq IPO in 2018.
Source: tracxn.com
Misses
Track record
Partners 7
- Andrew Frost
Partner
Board seats
No public record - Andrew Kozlov
Partner
Board seats
No public record - Brian McVeigh
Partner
Board seats
No public record - Dima Kuzmin
Partner
Board seats
No public record - Owen Smith
Partner
Board seats
No public record - Therese Liechtenstein
Partner
Board seats
2 current
- Tetsu Maruyama
Venture Partner
Board seats
No public record
Reputation 2
No reputation score — basis not established for this firm.
- 4BIO Capital investor profile - Fundraising Fox
fundraisingfox.com
- 4BIO Capital leads Cytospire Series A - GlobeNewswire
globenewswire.com
Contact
Published sources only
Published contact
- Website
- www.4biocapital.com
Published sources only
GlassVC lists only contact information the firm or its sources have published. We do not list personal emails, direct lines, or private addresses.
SOURCE: FIRM WEBSITE, AS PUBLISHED 2
What founders say
Founder-submitted · Verified identity and relationship
No founder reviews yet
Be the first founder to share your experience with 4BIO Capital. Reviews come from founders whose identity and relationship have been verified.
Write the first reviewMethodology
Tier basis — Latest vehicle (4BIO Ventures III) is reported as a $200–300M target rather than a verified close, so no tier_3 rule fires on verified evidence (tier_4). Tier reflects published scale and track-record signals. It is not a rating of the firm as a partner.
Figures are shown as published; conflicting figures are never averaged. Review dimension scores appear only once three founders have reviewed this firm; profiles below that threshold do not appear in rated lists.
The catalog does not yet carry per-figure citations or as-of dates: every figure on this page traces to the catalog record listed below, and that limit is stated rather than papered over. Corrections with a source: Suggest a correction.
Source record 2
- [1]
DATABASE · GlassVC catalog — Catalog record for 4BIO Capital — provenance: GlassVC catalog census, November 2026
↩ cites: AUM · Check size · Founded · HQ · Stages · Sectors · Funds · Track record · Reputation
- [2]
FIRM SITE · 4BIO Capital — Firm website, as published by the firm
PROFILE BUILT FROM PUBLIC SOURCES · 2 CATALOG SOURCES · LAST CHECKED NOV 2026
